Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Eyenovia, Inc.
  6. News
  7. Summary
    EYEN   US30234E1047

EYENOVIA, INC.

(EYEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

EYENOVIA, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)

06/16/2021 | 03:34pm EDT

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 16, 2021, Eyenovia, Inc. ("Eyenovia") held its 2021 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the stockholders: (1) elected each of Fredric N. Eshelman, Pharm.D., Tsontcho Ianchulev, M.D., M.P.H., Julia A. Haller, M.D., Curt H. LaBelle, M.D., M.B.A., Kenneth B. Lee, Jr., Ernest Mario, Ph.D., Charles E. Mather IV, and Anthony Y. Sun, M.D., to Eyenovia's Board of Directors for a term of one year to serve until the 2022 annual meeting of stockholders and until a successor is elected and qualified or until his or her earlier death, resignation or removal ("Election of Directors"); (2) approved an amendment to the Eyenovia, Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan ("Equity Plan Amendment") reserving an additional 1,250,000 shares of common stock for further issuance under such plan; and (3) ratified the appointment of Marcum LLP as Eyenovia's independent registered public accounting firm for the fiscal year ending December 31, 2021 ("Auditor Ratification"). A more complete description of each of these matters is set forth in Eyenovia's definitive proxy statement filed with the SEC on April 30, 2021.

The number of votes cast in favor or against or withheld by the stockholders and, where applicable, the number of abstentions and the number of broker nonvotes on each of the foregoing matters are set forth below.



1. Election of Directors



                                                    Shares Voted to
                                     Shares            Withhold
Nominee                            Voted For           Authority
Fredric N. Eshelman, Pharm.D.       6,390,266           4,444,559
Tsontcho Ianchulev, M.D., M.P.H     10,810,458            24,367
Julia A. Haller, M.D.               10,817,570            17,255
Curt H. LaBelle, M.D., M.B.A.       10,722,158           112,667
Kenneth B. Lee, Jr.                 10,523,232           311,593
Ernest Mario, Ph.D.                 6,413,881           4,420,944
Charles E. Mather IV                10,591,798           243,027
Anthony Y. Sun, M.D.                10,589,902           244,923




2. Equity Plan Amendment



       Shares         Shares Voted         Shares          Broker
     Voted For          Against          Abstaining       Nonvotes
      10,234,775          542,903           57,147         6,026,057




3. Auditor Ratification



       Shares         Shares Voted         Shares
     Voted For          Against          Abstaining
      16,834,329          12,882            13,671

© Edgar Online, source Glimpses

All news about EYENOVIA, INC.
09/17EYENOVIA : Arctic Vision Expand Licence Deal to Include Another Eye Drug
MT
09/17Arctic Vision Announces Addition of Novel Mydriatic Drug Mydcombi™ to Eyenovia Commerci..
CI
09/15EYENOVIA : Material Definitive Agreement (Form 8-K)
PU
09/15EYENOVIA, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
09/15Eyenovia, Inc. Enters into Amendment to Certain License Agreement with Arctic Vision (H..
CI
08/12EYENOVIA : Management's Discussion and Analysis of Financial Condition and Results of Oper..
AQ
08/11EYENOVIA : Announced positive topline data from its Phase 3 VISION-1 study evaluating Micr..
PU
08/11EYENOVIA, INC. : Results of Operations and Financial Condition, Other Events, Financial St..
AQ
08/11Eyenovia, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/11Eyenovia Reports Second Quarter 2021 Financial Results
GL
More news
Analyst Recommendations on EYENOVIA, INC.
More recommendations
Financials (USD)
Sales 2021 3,49 M - -
Net income 2021 -22,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -7,20x
Yield 2021 -
Capitalization 150 M 150 M -
Capi. / Sales 2021 43,0x
Capi. / Sales 2022 15,0x
Nbr of Employees 33
Free-Float 63,8%
Chart EYENOVIA, INC.
Duration : Period :
Eyenovia, Inc. Technical Analysis Chart | EYEN | US30234E1047 | MarketScreener
Technical analysis trends EYENOVIA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 5,78 $
Average target price 15,67 $
Spread / Average Target 171%
EPS Revisions
Managers and Directors
Sean Ianchulev President, CEO, Director & Chief Medical Officer
John P. Gandolfo Chief Financial Officer & Secretary
Fredric N. Eshelman Chairman
Luke Clauson VP-Engineering, Research & Development
Jennifer Clasby VP-Clinical Operations & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
EYENOVIA, INC.-4.62%150
JOHNSON & JOHNSON4.07%431 148
ROCHE HOLDING AG13.98%333 101
PFIZER, INC.14.34%239 966
NOVO NORDISK A/S56.26%238 738
ELI LILLY AND COMPANY44.35%220 952